LIST OF FIGURES

Figure 1.1. Schematic representation of structure of skin
Figure 1.2. Optical images of various types of wounds.
Figure 1.3. Schematic representation of phases of wound healing.
Figure 1.4. Features of an ideal wound dressing.
Figure 1.5. Structure of chitin.
Figure 1.6. Polymer chain arrangements in α-chitin.
Figure 1.7. Polymer chain arrangements in β-chitin.
Figure 1.8. Polymer chain arrangements in γ-chitin.
Figure 1.9. Structure of chitosan.
Figure 1.10. Crystal structure of ZnO.

Figure 3.1. Characterization of nZnO. (A) UV-Visible spectrum (B) DLS spectrum (C) XRD spectrum (D) SEM and (E) AFM image.

Figure 3.2. A) Photographs of α-chitin hydrogel, nZnO suspension, α-chitin hydrogel/nZnO composite bandage. B) FT-IR spectra of (a) α-chitin (b) nZnO (c) α-chitin + 0.05% nZnO (d) α-chitin + 0.1% nZnO. C) XRD spectra of (a) nZnO (b) α-chitin (c) α-chitin + 0.05% nZnO (d) α-chitin + 0.1% nZnO.

Figure 3.3. (A)-(C) SEM images of α-chitin, α-chitin +0.05% nZnO, α-chitin + 0.1% nZnO composite bandages respectively.

Figure 3.4. A) Photographs of β-chitin hydrogel. B) nZnO suspension. C) β-chitin hydrogel/nZnO composite bandage. D, E, F) SEM images of β-chitin control, β-chitin + 0.1% nZnO and β-chitin + 0.05% nZnO respectively. G) FT-IR spectra of composite bandages. H) XRD spectra of (a) nZnO control (b) β-chitin control (c) β-chitin + 0.05% nZnO and (d) β-chitin + 0.1% nZnO.

Figure 3.5 (A) Schematic representation of the chitosan hydrogel/nZnO composite bandage. (B, C, D) Photographs of the chitosan hydrogel, nZnO suspension, and chitosan hydrogel/nZnO mixture respectively. (E, F, G, H) Photographs of chitosan hydrogel/nZnO composite bandage. (I, J, K) SEM images of chitosan control, chitosan + 0.01% nZnO, and chitosan
+ 0.005% nZnO composite bandages, respectively. (L) SEM image of the chitosan + 0.01% nZnO composite bandage; white arrows indicate the nZnO particles.

**Figure 3.6.** FT-IR and XRD characterizations of CZBs. (A) FT-IR spectra of nZnO (spectrum a), chitosan control (spectrum b), chitosan + 0.005% nZnO (spectrum c), and chitosan + 0.01% nZnO (spectrum d). (B) XRD spectra of nZnO (spectrum a), chitosan control (spectrum b), chitosan + 0.005% nZnO (spectrum c), and chitosan + 0.01% nZnO (spectrum d).

**Figure 3.7.** Swelling ratio of composite bandages (A) α-chitin hydrogel/nZnO composite bandage (B) β-chitin hydrogel/nZnO composite bandage (C) Chitosan hydrogel/nZnO composite bandage.

**Figure 3.8.** *In vitro* biodegradation of composite bandages (A) α-chitin hydrogel/nZnO composite bandage (B) β-chitin hydrogel/nZnO composite bandage (C) Chitosan hydrogel/nZnO composite bandage.

**Figure 3.9.** Mechanical properties of composite bandages. (A, C, E) Tensile strength of α-chitin hydrogel/nZnO composite bandage, β-chitin hydrogel/nZnO composite bandage and Chitosan hydrogel/nZnO composite bandage respectively. (B, D, F) Elongation at break of α-chitin hydrogel/nZnO composite bandage, β-chitin hydrogel/nZnO composite bandage and Chitosan hydrogel/nZnO composite bandage respectively.

**Figure 3.10.** Hemostatic potential A) Blood clotting evaluation. B, C, D, E) Platelet activation evaluation on Kaltostat, α-chitin, α-chitin + 0.05 % nZnO, α-chitin + 0.1 % nZnO composite bandages respectively.

**Figure 3.11.** Schematic representation of the blood clotting induced by the composite bandage

**Figure 3.12.** A) Photographs of composite bandage, blood on bandage and bandage with blood clot. B) Blood clotting evaluation of composite bandages. C) SEM images of platelets attached on to the bandages.
Figure 3.13. (A, B, C) Photographs of the chitosan bandage, blood on the chitosan bandage, clotted blood on the CZB, respectively. (D) Whole-blood clotting evaluation of bandages.

Figure 3.14. A) Photographs of Antibacterial activity studies against *S. aureus* (1) α-chitin (2) α-chitin + 0.1 % nZnO (3) α-chitin + 0.05 % nZnO (4) α-chitin + 0.0.025 % nZnO (5) α-chitin + 0.01 % nZnO (6) Kaltostat (7) *S. aureus* control. B) Quantification of *S. aureus* (1) α-chitin (2) α-chitin + 0.1 % nZnO (3) α-chitin + 0.05 % nZnO (4) α-chitin + 0.0.025 % nZnO (5) α-chitin + 0.01 % nZnO (6) Kaltostat (7) *S. aureus* control.

Figure 3.15. Antibacterial activity evaluation of the composite bandages against *S. aureus* at different time points. Photographic representation of antibacterial activity at (A) 6h (B) 12 h and (C) 24 h. (D) Quantification of the *S. aureus* after different time points in interaction with the composite bandages. In the figure, (A) *S. aureus* control (B) α-chitin control (C) α-chitin + 0.01%nZnO (D) α-chitin + 0.025%nZnO (E) α-chitin + 0.05%nZnO (F) α-chitin + 0.1%nZnO (G) Kaltostat.

Figure 3.16. A) Photographs of Antibacterial activity studies against *E. coli* (1) α-chitin (2) α-chitin + 0.1 % nZnO (3) α-chitin + 0.05 % nZnO (4) α-chitin + 0.0.025 % nZnO (5) α-chitin + 0.01 % nZnO (6) Kaltostat (7) *E. coli* control. B) Quantification of *E. coli* (1) α-chitin (2) α-chitin + 0.1 % nZnO (3) α-chitin + 0.05 % nZnO (4) α-chitin + 0.0.025 % nZnO (5) α-chitin + 0.01 % nZnO (6) Kaltostat (7) *E. coli* control.

Figure 3.17. Antibacterial activity evaluation of the composite bandages against *E. coli* at different time points. Photographic representation of antibacterial activity at (A) 6h (B) 12 h and (C) 24 h. (D) Quantification of the *E. coli* after different time points in interaction with the composite bandages. In the figure, (A) *E. coli* control (B) α-chitin control (C) α-chitin + 0.01%nZnO (D) α-chitin + 0.025%nZnO (E) α-chitin + 0.05%nZnO (F) α-chitin + 0.1%nZnO (G) Kaltostat.

Figure 3.18. Schematic representation of antibacterial mechanism of nZnO.
Figure 3.19. A) Photographs of antibacterial activity and B) Quantification of antibacterial activity against *S. aureus* (1) *S. aureus* control (2) Kaltostat (3) β-chitin control (4) β-chitin + 0.1 % nZnO (5) β-chitin + 0.05 % nZnO (6) β-chitin + 0.025 % nZnO (7) β-chitin + 0.01 % nZnO.

Figure 3.20. Antibacterial activity evaluation of the composite bandages against *S. aureus* at different time points. Photographic representation of antibacterial activity at (A) 6h (B) 12 h and (C) 24 h. (D) Quantification of the *S. aureus* after different time points in interaction with the composite bandages. In the figure, (A) *S.aureus* control (B) β-chitin control (C) β-chitin + 0.01%nZnO (D) β-chitin + 0.025%nZnO (E) β-chitin + 0.05%nZnO (F) β-chitin + 0.1%nZnO (G) Kaltostat.

Figure 3.21. A) Photographs and B) Quantification data of antibacterial activity studies against *E. coli* (1) *E. coli* control (2) Kaltostat (3) β-chitin control (4) β-chitin + 0.1 % nZnO (5) β-chitin + 0.05 % nZnO (6) β-chitin + 0.025 % nZnO (7) β-chitin + 0.01 % nZnO. C) Antifungal study against *C. albicans* (1) *C. albicans* control (2) Kaltostat (3) β-chitin control (4) β-chitin + 0.1 % nZnO (5) β-chitin + 0.05 % nZnO (6) β-chitin + 0.025 % nZnO (7) β-chitin + 0.01 % nZnO.

Figure 3.22. Antibacterial activity evaluation of the composite bandages against *E. coli* at different time points. Photographic representation of antibacterial activity at (A) 6h (B) 12 h and (C) 24 h. (D) Quantification of the *E. coli* after different time points in interaction with the composite bandages. In the figure, (A) *E. coli* control (B) β-chitin control (C) β-chitin + 0.01%nZnO (D) β-chitin + 0.025%nZnO (E) β-chitin + 0.05%nZnO (F) β-chitin + 0.1%nZnO (G) Kaltostat.

Figure 3.23. Photographs showing the antibacterial activity of composite bandages against (A) *S.aureus* [(1) chitosan control (2) chitosan + 0.01% nZnO (3) chitosan + 0.05% nZnO (4) chitosan + 0.025% nZnO (5) chitosan + 0.001% nZnO (6) *S. aureus* control] and (B) *E.coli* [(1) chitosan control (2) chitosan + 0.01% nZnO (3) chitosan + 0.05% nZnO (4) chitosan +
0.025% nZnO (5) chitosan + 0.001% nZnO (6) *E. coli* control. C) Quantification of the antibacterial activity.

**Figure 3.24.** Antibacterial activity evaluation of the composite bandages against *S. aureus* at different time points. Photographic representation of antibacterial activity at (A) 6h (B) 12 h and (C) 24 h. (D) Quantification of the *S. aureus* after different time points in interaction with the composite bandages. In the figure, (A) *S.aureus* control (B) Chitosan control (C) Chitosan + 0.001% nZnO (D) Chitosan + 0.0025%nZnO (E) Chitosan + 0.005%nZnO (F) Chitosan + 0.01%nZnO (G) Kaltostat.

**Figure 3.25.** Antibacterial activity evaluation of the composite bandages against *E. coli* at different time points. Photographic representation of antibacterial activity at (A) 6h (B) 12 h and (C) 24 h. (D) Quantification of the *E. coli* after different time points in interaction with the composite bandages. In the figure, (A) *E. coli* control (B) Chitosan control (C) Chitosan + 0.001% nZnO (D) Chitosan + 0.0025%nZnO (E) Chitosan + 0.005%nZnO (F) Chitosan + 0.01%nZnO (G) Kaltostat.

**Figure 3.26.** Photographs of antifungal activity studies against *C. albicans*.

**Figure 3.27.** Antifungal activity evaluation of the composite bandages against *C. albicans* at different time points. Photographic representation of antifungal activity at (A) 6h (B) 12 h and (C) 24 h. (D) Quantification of the *C. albicans* after different time points in interaction with the composite bandages. In the figure, (A) *C. albicans* control (B) α-chitin control (C) α-chitin + 0.01%nZnO (D) α-chitin + 0.025%nZnO (E) α-chitin + 0.05%nZnO (F) α-chitin + 0.1%nZnO (G) Kaltostat.

**Figure 3.28.** Schematic representation of the antifungal mechanism of nZnO.

**Figure 3.29.** Antifungal activity studies against *C. albicans*.

**Figure 3.30.** Antifungal activity evaluation of the composite bandages against *C. albicans* at different time points. Photographic representation of antifungal activity at (A) 6h (B) 12 h and (C) 24 h. (D) Quantification of the *C. albicans* after different time points in interaction with the composite bandages. In the figure, (A) *C. albicans* control (B) β-chitin
control (C) β-chitin + 0.01%nZnO (D) β-chitin + 0.025%nZnO (E) β-chitin + 0.05%nZnO (F) β-chitin + 0.1%nZnO (G) Kaltostat.

**Figure 3.31.** Photographs of antifungal activity studies against C. albicans.

**Figure 3.32.** Antifungal activity evaluation of the composite bandages against C. albicans at different time points. Photographic representation of antifungal activity at (A) 6h (B) 12 h and (C) 24 h. (D) Quantification of the C. albicans after different time points in interaction with the composite bandages. In the figure, (A) C. albicans control (B) Chitosan control (C) Chitosan + 0.001% nZnO (D) Chitosan + 0.0025%nZnO (E) Chitosan + 0.005%nZnO (F) Chitosan + 0.01%nZnO (G) Kaltostat.

**Figure 3.33.** A) Cell viability study using HDF cells. B, C & D) DAPI staining of HDF cells attached on α-chitin, α-chitin + 0.05 % nZnO, α-chitin + 0.1% nZnO composite bandages respectively. E, F & G) SEM images of cell attachment on α-chitin, α-chitin + 0.05 % nZnO, α-chitin + 0.1% nZnO composite bandages respectively.

**Figure 3.34.** A, D & G) Laser confocal images of the surface of chitin, chitin+ 0.01% nZnO and chitin + 0.1% nZnO bandage respectively. B, E & H) Phalloidin dye stained confocal images of the HDF cells attached on chitin, chitin+ 0.01% nZnO and chitin + 0.1% nZnO bandage respectively. C, F & I) Merged confocal images of chitin, chitin+ 0.01% nZnO and chitin + 0.1% nZnO bandage respectively.

**Figure 3.35.** A, D, G) Laser confocal images of vertical view of chitin, chitin+ 0.01% nZnO and chitin + 0.1% nZnO bandage respectively. B, E & H) Phalloidin dye stained confocal images of the HDF cells infiltrated to chitin, chitin+ 0.01% nZnO and chitin + 0.1% nZnO bandage respectively. C, F & I) Merged confocal images of chitin, chitin+ 0.01% nZnO and chitin + 0.1% nZnO bandage respectively.

**Figure 3.36.** A) Cell viability study using HDF cells. B, C, D) DAPI staining of HDF cells attached on β-chitin, β-chitin + 0.05 % nZnO, β-chitin + 0.1% nZnO composite bandages respectively. E, F, G) SEM images of cell
attachment on β-chitin, β-chitin + 0.05 % nZnO, β-chitin + 0.1 % nZnO composite bandages respectively.

Figure 3.37.  A, D & G) Laser confocal images of the surface of β-chitin, β-chitin + 0.01 % nZnO and β-chitin + 0.1 % nZnO bandage respectively. B, E, H) Phalloidin dye stained confocal images of the HDF cells attached on β-chitin, β-chitin + 0.01 % nZnO and β-chitin + 0.1 % nZnO bandage respectively. C, F, I) Merged confocal images of β-chitin, β-chitin + 0.01 % nZnO and β-chitin + 0.1 % nZnO bandage respectively. J, M, P) Z-stacked laser confocal images of the surface of β-chitin, β-chitin + 0.01 % nZnO and β-chitin + 0.1 % nZnO bandage respectively. K, N, Q) Phalloidin dye stained Z-stacked confocal images of the HDF cells attached on β-chitin, β-chitin + 0.01 % nZnO and β-chitin + 0.1 % nZnO bandage respectively. L, O, R) Merged Z-stacked confocal images of β-chitin, β-chitin + 0.01 % nZnO and β-chitin + 0.1 % nZnO bandage respectively.

Figure 3.38.  A) Cell viability study using HDF cells. B, C, D, E, F) SEM images of cell attachment on bandages. G, H, I, J, K) DAPI staining of HDF cells attached on bandages.

Figure 3.39.  A, F) Laser confocal images of the surface and lateral view of chitosan bandage with cells respectively. B, G) Confocal images of the surface and lateral view of chitosan+ 0.001 % nZnO bandage respectively. C, H) Confocal images of the surface and lateral view of chitosan+ 0.0025 % nZnO bandage respectively. D, I) Confocal images of the surface and lateral view of chitosan+ 0.005 % nZnO bandage respectively. E, G) Confocal images of the surface and lateral view of chitosan+ 0.01 % nZnO bandage respectively.

Figure 3.40.  A) Photographs of bare and wounds treated with composite bandages B) Wound area closure evaluation data.

Figure 3.41.  A) H & E stained images of wound tissue. In week 1 and 3, first row images represent the lower magnification images and second row
represents the magnified portion inside the inset. **B**) Re-epithelialization data.

**Figure 3.42.** **A**) Picro-Sirius red stained images of wound tissue. In week 1 and 3, first row images represent the lower magnification images and second row represents the magnified portion inside the inset. **B**) Quantification of collagen deposition.

**Figure 3.43.** *In vivo* antimicrobial activity of the β-chitin hydrogel/nZnO composite bandages. **A**) Bare wound **B**) β-Chitin control  **C**) β-Chitin + 0.025% nZnO  **D**) β-Chitin + 0.1% nZnO  **E**) Kaltostat (* indicate p < 0.05 compared to the bare wound, control bandage and Kaltostat treated wounds).

**Figure 3.44.** *In vivo* serum inflammatory cytokine analysis of IFN-γ.

**Figure 3.45.** *In vivo* serum inflammatory cytokine analysis of TNF-α.

**Figure 3.46.** Photographs of an *in vivo* wound healing study.

**Figure 3.47.** Photomicrographs of hematoxylin and eosin (H&E)-stained (A and B) bare wound, (C and D) Kaltostat-treated wounds, (E and F) chitosan-control-treated wounds, (G and H) chitosan + 0.005% nZnO bandage-treated wounds, and (I and J) chitosan + 0.01% nZnO bandage-treated wounds. Panels A, C, E, G, and I are low-magnification images and panels B, D, F, H, and J are high-magnification images.

**Figure 3.48.** Photomicrographs of Picro-Sirius Red-stained histology sections: (A and B) bare wound, (C and D) Kaltostat-treated wounds, (E and F) chitosan-control-treated wounds, (G and H) chitosan + 0.005% nZnO bandage-treated wounds, and (I and J) chitosan + 0.01% nZnO bandage-treated wounds. Panels A, C, E, G, and I are low-magnification images and panels B, D, F, H, and J are high-magnification images.

**Figure 3.49.** (A) Evaluation of the wound area closure and (B) study of the collagen deposition area.

**Figure 3.50.** *In vivo* antimicrobial activity of the chitosan hydrogel/nZnO composite bandages. **A**) Bare wound **B**) Chitosan control  **C**) Chitosan + 0.005% nZnO  **D**) Chitosan + 0.01% nZnO  **E**) Kaltostat.
**Figure 3.51.** *In vivo* serum inflammatory cytokine analysis of IFN-γ.

**Figure 3.52.** *In vivo* serum inflammatory cytokine analysis of TNF-α.